Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction

药代动力学 氢氯噻嗪 交叉研究 医学 药理学 置信区间 贝那普利 最大值 缬沙坦 不利影响 泌尿科 化学 内科学 安慰剂 血压 替代医学 病理
作者
Jiang Ji,Lei Tian,Yanqin Huang,Shangzhe Xie,Liang Xu,H Liu,Y Li
出处
期刊:International Journal of Clinical Pharmacology and Therapeutics [Dustri-Verlag]
卷期号:49 (12): 756-764 被引量:5
标识
DOI:10.5414/cp201583
摘要

To compare the pharmacokinetic (PK) profiles and evaluate the PK interaction of hydrochlorothiazide (HCTZ) used alone and in combination with benazepril (BENA) or valsartan (VAL) in healthy Chinese volunteers.Data from two Phase I clinical trials (Study A and Study B) were combined and analyzed. Study A was an open, randomized, three-period crossover study. Eligible healthy male Chinese volunteers were randomly assigned to receive a single dose of the HCTZ (25 mg), BENA (20 mg) or HCTZ/BENA (25/20 mg). Study B was an open randomized, two-period crossover study of VAL/HCTZ (160/12.5 mg) in two formulations. A 7-day washout period was designed between alternate formulations in both studies. Multiple blood samples were collected up to 48 h post-dose, and plasma concentrations of HCTZ were analyzed using high performance liquid chromatography with tandem mass spectrometric detection (HPLC-MS/MS) system. Adverse events (AEs) were monitored and documented throughout the study period.12 subjects completed Study A and 18 subjects completed Study B. Mean maximum plasma concentration (C(max)) was 168, 121 and 418 ng/ml and mean exposure (AUC(0-48 h)) was 1,160, 955 and 2,801 ng × h/ml following a single dose of HCTZ (25 mg) alone, BENA/HCTZ (20/25 mg) and VAL/HCTZ (160/12.5 mg), respectively. There was significant decrease in C(max) (90% confidence interval: 64.4 - 78.0%) and AUC(0-48 h) (90% confidence interval: 75.9 - 89.5%) of HCTZ with BENA co-administration, whereas concomitant VAL with HCTZ led to significant increase (approximate 1.5-fold) in C(max) and AUC(0-48 h) of plasma HCTZ even without dose normalizing. The apparent terminal half-life (t(1/2)) and the time to C(max) (tmax) were unchanged between the two studies. Overall, HCTZ alone as well as in combination with BENA and VAL was well tolerated within the scope of the current studies in Chinese health volunteers.BENA decreased the bioavailability of HCTZ in Chinese healthy volunteers while VAL greatly increased the concentration of HCTZ in plasma during coadministration. The combination of HCTZ with BENA or VAL was safe and well tolerated.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小魏发布了新的文献求助20
刚刚
晨丶完成签到,获得积分10
刚刚
权瑞松发布了新的文献求助10
1秒前
暴躁的冬易完成签到 ,获得积分10
1秒前
PENGQIDU完成签到 ,获得积分10
1秒前
2秒前
科研通AI6.4的应助被sui采纳,获得10
2秒前
2秒前
英姑的应助被LUXURY采纳,获得10
4秒前
4秒前
英俊的铭的应助被Ian采纳,获得10
4秒前
匀加速发布了新的文献求助10
5秒前
阿盛发布了新的文献求助10
6秒前
6秒前
科目三的应助被momo采纳,获得10
6秒前
Stella完成签到,获得积分10
6秒前
7秒前
7秒前
7秒前
TRY发布了新的文献求助10
10秒前
安静稚晴关注了科研通微信公众号
11秒前
2953685951发布了新的文献求助10
11秒前
天天快乐的应助被rootree采纳,获得10
11秒前
11秒前
马秀玲完成签到,获得积分10
11秒前
Jane完成签到 ,获得积分10
12秒前
饼的书发布了新的文献求助30
12秒前
我要资料啊完成签到,获得积分10
12秒前
13秒前
13秒前
QQ完成签到,获得积分10
13秒前
在水一方的应助被大大咧咧采纳,获得10
13秒前
Light完成签到,获得积分10
14秒前
14秒前
14秒前
天天快乐的应助被LML采纳,获得10
15秒前
15秒前
科研通AI6.3的应助被ww采纳,获得30
16秒前
杨旺旺完成签到,获得积分10
16秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183263
求助须知:如何正确求助?哪些是违规求助? 9572532
关于积分的说明 21826339
捐赠科研通 7780187
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558131
邀请新用户注册赠送积分活动 2480239